FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133463284> ?p ?o ?g. }

• W3133463284 abstract "Breast cancer is one of the most commonly diagnosed malignancies. Although endocrine therapy improves the survival of patients with hormone receptor (HR)-positive breast cancer, the post-endocrine therapy strategy for metastatic breast cancer remains challenging. Herein, we report two patients who benefited from antiestrogen agents combined with an immunotherapy regimen to support the notion that an immunotherapy combination regimen may be a potential treatment for patients with HR-positive metastatic breast cancer post-endocrine therapy. Case 1 involved a patient with relapsed breast cancer with ovarian and brain metastases after endocrine therapy. After undergoing surgery for the ovarian lesions, she received three cycles of chemotherapy. Given that the lesions in the brain did not change, chemotherapy was discontinued. A high T cell receptor (TCR) repertoire (high Shannon index and clonality) was observed in the tumor. Considering the patient's preference and safety, and the efficacy of immunotherapy, she was administered with letrozole combined with pembrolizumab. The patient achieved a partial response, and the progression-free survival (PFS) was more than 21 months. Case 2 involved a patient with breast cancer with multiple bone metastases. After failure of combined radiotherapy and chemotherapy, the patient received tamoxifen combined with pembrolizumab based on the patient's preference and clinical biomarkers of a positive differentiation cluster of eight tumor-infiltrating lymphocytes and a high TCR repertoire (high Shannon index and clonality) in the tumor. The patient's bone pain and biomarkers were relieved after the treatment. The patients completed six cycles of pembrolizumab, and the PFS was more than 21 months. In conclusion, our study confirmed that antiestrogen agents combined with an immunotherapy regimen is a promising treatment for patients with HR-positive metastatic breast cancer." @default.
• W3133463284 created "2021-03-01" @default.
• W3133463284 creator A5008123152 @default.
• W3133463284 creator A5012553842 @default.
• W3133463284 creator A5024120345 @default.
• W3133463284 creator A5024950433 @default.
• W3133463284 creator A5033704842 @default.
• W3133463284 creator A5061294959 @default.
• W3133463284 creator A5062665642 @default.
• W3133463284 creator A5066011017 @default.
• W3133463284 creator A5079333379 @default.
• W3133463284 date "2021-02-22" @default.
• W3133463284 modified "2023-10-16" @default.
• W3133463284 title "Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression" @default.
• W3133463284 cites W1601679057 @default.
• W3133463284 cites W1992533338 @default.
• W3133463284 cites W2033672070 @default.
• W3133463284 cites W2039123767 @default.
• W3133463284 cites W2118728607 @default.
• W3133463284 cites W2134878729 @default.
• W3133463284 cites W2161977537 @default.
• W3133463284 cites W2183855403 @default.
• W3133463284 cites W2290950904 @default.
• W3133463284 cites W2295482860 @default.
• W3133463284 cites W2466558384 @default.
• W3133463284 cites W2552099557 @default.
• W3133463284 cites W2744067212 @default.
• W3133463284 cites W2763875663 @default.
• W3133463284 cites W2790745355 @default.
• W3133463284 cites W2791308824 @default.
• W3133463284 cites W2889583624 @default.
• W3133463284 cites W2892043300 @default.
• W3133463284 cites W2897422388 @default.
• W3133463284 cites W2945564879 @default.
• W3133463284 cites W2947588609 @default.
• W3133463284 cites W2965988302 @default.
• W3133463284 cites W2982314248 @default.
• W3133463284 cites W2982542437 @default.
• W3133463284 cites W2985693568 @default.
• W3133463284 cites W3008954267 @default.
• W3133463284 cites W3106414058 @default.
• W3133463284 doi "https://doi.org/10.3389/fimmu.2021.610149" @default.
• W3133463284 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7939121" @default.
• W3133463284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33692787" @default.
• W3133463284 hasPublicationYear "2021" @default.
• W3133463284 type Work @default.
• W3133463284 sameAs 3133463284 @default.
• W3133463284 citedByCount "5" @default.
• W3133463284 countsByYear W31334632842021 @default.
• W3133463284 countsByYear W31334632842022 @default.
• W3133463284 countsByYear W31334632842023 @default.
• W3133463284 crossrefType "journal-article" @default.
• W3133463284 hasAuthorship W3133463284A5008123152 @default.
• W3133463284 hasAuthorship W3133463284A5012553842 @default.
• W3133463284 hasAuthorship W3133463284A5024120345 @default.
• W3133463284 hasAuthorship W3133463284A5024950433 @default.
• W3133463284 hasAuthorship W3133463284A5033704842 @default.
• W3133463284 hasAuthorship W3133463284A5061294959 @default.
• W3133463284 hasAuthorship W3133463284A5062665642 @default.
• W3133463284 hasAuthorship W3133463284A5066011017 @default.
• W3133463284 hasAuthorship W3133463284A5079333379 @default.
• W3133463284 hasBestOaLocation W31334632841 @default.
• W3133463284 hasConcept C121608353 @default.
• W3133463284 hasConcept C126322002 @default.
• W3133463284 hasConcept C143998085 @default.
• W3133463284 hasConcept C2775930923 @default.
• W3133463284 hasConcept C2776694085 @default.
• W3133463284 hasConcept C2777176818 @default.
• W3133463284 hasConcept C2777701055 @default.
• W3133463284 hasConcept C2778336483 @default.
• W3133463284 hasConcept C2778812593 @default.
• W3133463284 hasConcept C2780057760 @default.
• W3133463284 hasConcept C2781413609 @default.
• W3133463284 hasConcept C509974204 @default.
• W3133463284 hasConcept C530470458 @default.
• W3133463284 hasConcept C71924100 @default.
• W3133463284 hasConceptScore W3133463284C121608353 @default.
• W3133463284 hasConceptScore W3133463284C126322002 @default.
• W3133463284 hasConceptScore W3133463284C143998085 @default.
• W3133463284 hasConceptScore W3133463284C2775930923 @default.
• W3133463284 hasConceptScore W3133463284C2776694085 @default.
• W3133463284 hasConceptScore W3133463284C2777176818 @default.
• W3133463284 hasConceptScore W3133463284C2777701055 @default.
• W3133463284 hasConceptScore W3133463284C2778336483 @default.
• W3133463284 hasConceptScore W3133463284C2778812593 @default.
• W3133463284 hasConceptScore W3133463284C2780057760 @default.
• W3133463284 hasConceptScore W3133463284C2781413609 @default.
• W3133463284 hasConceptScore W3133463284C509974204 @default.
• W3133463284 hasConceptScore W3133463284C530470458 @default.
• W3133463284 hasConceptScore W3133463284C71924100 @default.
• W3133463284 hasFunder F4320321001 @default.
• W3133463284 hasLocation W31334632841 @default.
• W3133463284 hasLocation W31334632842 @default.
• W3133463284 hasLocation W31334632843 @default.
• W3133463284 hasOpenAccess W3133463284 @default.
• W3133463284 hasPrimaryLocation W31334632841 @default.
• W3133463284 hasRelatedWork W1040971774 @default.
• W3133463284 hasRelatedWork W1966100371 @default.
• W3133463284 hasRelatedWork W2067013005 @default.
• W3133463284 hasRelatedWork W2084025059 @default.

• next